Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 12.31
INCY's Cash-to-Debt is ranked lower than
78% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. INCY: 12.31 )
Ranked among companies with meaningful Cash-to-Debt only.
INCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.37 Max: No Debt
Current: 12.31
Equity-to-Asset 0.60
INCY's Equity-to-Asset is ranked lower than
85% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INCY: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
INCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.19 Max: 0.92
Current: 0.6
-1.83
0.92
Piotroski F-Score: 4
Altman Z-Score: 25.10
Beneish M-Score: 0.35
WACC vs ROIC
12.94%
-7.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -1.99
INCY's Operating Margin % is ranked higher than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. INCY: -1.99 )
Ranked among companies with meaningful Operating Margin % only.
INCY' s Operating Margin % Range Over the Past 10 Years
Min: -4064.53  Med: -2.74 Max: 13.11
Current: -1.99
-4064.53
13.11
Net Margin % -8.72
INCY's Net Margin % is ranked higher than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. INCY: -8.72 )
Ranked among companies with meaningful Net Margin % only.
INCY' s Net Margin % Range Over the Past 10 Years
Min: -4565.45  Med: -21.09 Max: 9.43
Current: -8.72
-4565.45
9.43
ROE % -23.44
INCY's ROE % is ranked higher than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. INCY: -23.44 )
Ranked among companies with meaningful ROE % only.
INCY' s ROE % Range Over the Past 10 Years
Min: 14.59  Med: 24.94 Max: 35.29
Current: -23.44
14.59
35.29
ROA % -7.31
INCY's ROA % is ranked higher than
89% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. INCY: -7.31 )
Ranked among companies with meaningful ROA % only.
INCY' s ROA % Range Over the Past 10 Years
Min: -70.43  Med: -15.38 Max: 7.88
Current: -7.31
-70.43
7.88
ROC (Joel Greenblatt) % -53.90
INCY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. INCY: -53.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INCY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4727.38  Med: -134.72 Max: 115.22
Current: -53.9
-4727.38
115.22
3-Year Revenue Growth Rate 33.50
INCY's 3-Year Revenue Growth Rate is ranked higher than
80% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. INCY: 33.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INCY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.4  Med: 21.9 Max: 523.4
Current: 33.5
-61.4
523.4
GuruFocus has detected 5 Warning Signs with Incyte Corp $INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

INCY Guru Trades in Q2 2016

George Soros 7,500 sh (New)
Joel Greenblatt 142,607 sh (+171.63%)
Frank Sands 4,467,286 sh (+16.96%)
Paul Tudor Jones 81,409 sh (+5.18%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Ken Fisher 14,818 sh (-0.14%)
Jim Simons 164,567 sh (-45.87%)
Eaton Vance Worldwide Health Sciences Fund 363,900 sh (-15.25%)
» More
Q3 2016

INCY Guru Trades in Q3 2016

Jana Partners 58,385 sh (New)
John Burbank 243,396 sh (New)
Steven Cohen 68,000 sh (New)
Andreas Halvorsen 503,645 sh (New)
Pioneer Investments 80,822 sh (New)
Ken Fisher 14,917 sh (+0.67%)
Vanguard Health Care Fund 16,227,748 sh (unchged)
Frank Sands 4,124,074 sh (-7.68%)
Joel Greenblatt 108,099 sh (-24.20%)
George Soros 5,200 sh (-30.67%)
Jim Simons 62,900 sh (-61.78%)
Paul Tudor Jones 10,933 sh (-86.57%)
Eaton Vance Worldwide Health Sciences Fund 237,999 sh (-34.60%)
» More
Q4 2016

INCY Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 91,970 sh (New)
Pioneer Investments 623,117 sh (+670.97%)
Steven Cohen 438,801 sh (+545.30%)
Jana Partners 86,616 sh (+48.35%)
Andreas Halvorsen 730,452 sh (+45.03%)
Ken Fisher 14,917 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Frank Sands 3,652,652 sh (-11.43%)
Vanguard Health Care Fund 11,635,908 sh (-28.30%)
Joel Greenblatt 59,202 sh (-45.23%)
Paul Tudor Jones 4,203 sh (-61.56%)
John Burbank 63,593 sh (-73.87%)
Eaton Vance Worldwide Health Sciences Fund 228,436 sh (-4.02%)
» More
Q1 2017

INCY Guru Trades in Q1 2017

Jeremy Grantham 1,500 sh (New)
Frank Sands 4,250,593 sh (+16.37%)
Ken Fisher 15,050 sh (+0.89%)
Paul Tudor Jones Sold Out
Jana Partners Sold Out
Pioneer Investments 561,063 sh (-9.96%)
Joel Greenblatt 51,406 sh (-13.17%)
Vanguard Health Care Fund 9,256,598 sh (-20.45%)
Manning & Napier Advisors, Inc 55,375 sh (-39.79%)
Andreas Halvorsen 433,978 sh (-40.59%)
John Burbank 19,983 sh (-68.58%)
Steven Cohen 14,600 sh (-96.67%)
Eaton Vance Worldwide Health Sciences Fund 198,561 sh (-13.08%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:OTCPK:ALIOY, NAS:VRTX, NAS:ALXN, OTCPK:GIKLY, NAS:BMRN, OTCPK:NVZMF, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:CSLLY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO, NAS:REGN, NAS:BIVV, NAS:IONS, NAS:ALNY, NAS:EXEL, NAS:UTHR, NAS:ARIA » details
Traded in other countries:INCY.Austria, ICY.Germany,
Headquarter Location:USA
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug is Jakafi, a myelofibrosis and polycythemia vera treatment, which has been partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs.

Top Ranked Articles about Incyte Corp

CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments
Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments
FDA Rejects Eli Lilly, Incyte's Commercialization Application Shares tumbled after agency did not approve the companies' rheumatoid arthritis treatment
The U.S. Food and Drug Administration did not approve the marketing application for baricitinib, a medication that Eli Lilly and Co. (NYSE:LLY) is developing with Incyte Corp. (NASDAQ:INCY) for treating patients with rheumatoid arthritis, according to a news release published through Business Wire. Read more...
Weekly CFO Sells Highlight HP, Incyte insiders sell shares
According to GuruFocus Insider Data, the recent CFO sells were: HP Inc. (NYSE:HPQ) and Incyte Corp. (NASDAQ:INCY). Read more...
Incyte Insider Trims Position CFO sells 41,528 shares
David Gryska (Insider Trades), CFO and executive vice president of Incyte Corp. (INCY), sold 41,528 shares of the company on April 10. The transaction, Gryska’s only one with the company since at least 2013, was made for $138 per share, for a total transaction of $5,730,864. Read more...
Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences Viking Global adds to biotech holdings with 7.8% of shares
Andreas Halvorsen (Trades, Portfolio)’s $30 billion Viking Global hedge fund has invested in a new class of cancer drugs being developed by Calithera Biosciences Inc. (NASDAQ:CALA), it announced on Tuesday evening, via a stake worth 7.8% of its shares. Read more...

Ratios

vs
industry
vs
history
PB Ratio 28.46
INCY's PB Ratio is ranked lower than
98% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. INCY: 28.46 )
Ranked among companies with meaningful PB Ratio only.
INCY' s PB Ratio Range Over the Past 10 Years
Min: 24.39  Med: 60.26 Max: 391.93
Current: 28.46
24.39
391.93
PS Ratio 21.32
INCY's PS Ratio is ranked lower than
65% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. INCY: 21.32 )
Ranked among companies with meaningful PS Ratio only.
INCY' s PS Ratio Range Over the Past 10 Years
Min: 7.17  Med: 21.32 Max: 239.71
Current: 21.32
7.17
239.71
Price-to-Operating-Cash-Flow 767.89
INCY's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. INCY: 767.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.19  Med: 87.05 Max: 852.8
Current: 767.89
7.19
852.8
Current Ratio 2.69
INCY's Current Ratio is ranked lower than
54% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. INCY: 2.69 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.67 Max: 21.14
Current: 2.69
1.51
21.14
Quick Ratio 2.68
INCY's Quick Ratio is ranked lower than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INCY: 2.68 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 2.68
1.51
21.14
Days Inventory 21.33
INCY's Days Inventory is ranked higher than
86% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. INCY: 21.33 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 46.41 Max: 323.15
Current: 21.33
14.49
323.15
Days Sales Outstanding 72.91
INCY's Days Sales Outstanding is ranked higher than
61% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. INCY: 72.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 45.23 Max: 6447.52
Current: 72.91
12.25
6447.52
Days Payable 470.25
INCY's Days Payable is ranked higher than
94% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. INCY: 470.25 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 2972.25 Max: 32457.1
Current: 470.25
407.13
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
INCY's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. INCY: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8  Med: -9.2 Max: -0.6
Current: -5
-17.8
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 154.46
INCY's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. INCY: 154.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INCY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23  Med: 8.49 Max: 3615
Current: 154.46
1.23
3615
Price-to-Tangible-Book 50.41
INCY's Price-to-Tangible-Book is ranked lower than
99.99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INCY: 50.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INCY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91  Med: 5.76 Max: 340.56
Current: 50.41
0.91
340.56
Price-to-Intrinsic-Value-Projected-FCF 71.86
INCY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
95% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. INCY: 71.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INCY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 9.91  Med: 35.72 Max: 145.06
Current: 71.86
9.91
145.06
Price-to-Median-PS-Value 1.01
INCY's Price-to-Median-PS-Value is ranked lower than
57% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. INCY: 1.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INCY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.82 Max: 10.23
Current: 1.01
0.11
10.23
Earnings Yield (Greenblatt) % -0.30
INCY's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. INCY: -0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INCY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.6 Max: 1.3
Current: -0.3
0.1
1.3

More Statistics

Revenue (TTM) (Mil) $1,226
EPS (TTM) $ -0.55
Beta1.81
Short Percentage of Float2.40%
52-Week Range $71.75 - 153.15
Shares Outstanding (Mil)204.77

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,435 1,618 1,986
EPS ($) -0.49 0.46 1.42
EPS without NRI ($) -0.49 0.46 1.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
75.41%
Dividends per Share ($)
» More Articles for INCY

Headlines

Articles On GuruFocus.com
CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and May 03 2017 
Eaton Vance Worldwide Health Sciences Fund 1st Quarter Investment Report May 02 2017 
Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Apr 28 2017 
Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments Apr 28 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation Apr 20 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporati Apr 19 2017 
FDA Rejects Eli Lilly, Incyte's Commercialization Application Apr 18 2017 
Weekly CFO Sells Highlight Apr 17 2017 
U.S. FDA Issues Complete Response Letter for Baricitinib Apr 14 2017 
Incyte Insider Trims Position Apr 12 2017 

More From Other Websites
ETFs with exposure to Incyte Corp. : May 26, 2017 May 26 2017
Blog Coverage: Amgen Announces New Data from the FOURIER Trial May 23 2017
Incyte to Present at Upcoming Investor Conferences May 22 2017
Incyte Was the S&P 500’s Top Gainer on May 18 May 22 2017
Cramer's lightning round: I've got a message for the struggling Gilead Sciences May 19 2017
Bristol-Incyte Match Beats Dow's Merck In Combination Trials May 19 2017
Biotech Breakout Ahead? Incyte Rising On Success With Merk, Bristol-Myers May 19 2017
Company News for May 19, 2017 May 19 2017
The Most Notable Abstracts Released Ahead Of ASCO 2017 May 19 2017
Mercadolibre, Inc. Called a Great Growth Stock and Incyte Corporation Rockets on Positive... May 19 2017
Where buyers flock after a sell-off May 18 2017
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor May 18 2017
Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer May 18 2017
The Hot Stock: Incyte Climbs May 18 2017
Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed May 18 2017
Concert Pharma Falls After Clinical Hold on Hair Loss Drug May 18 2017
A $25 billion biotech's stock is popping on its promising cancer data May 18 2017
US STOCKS-Trump slump set to extend into second day May 18 2017
US STOCKS-Futures fall as Trump tumult continues May 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)